IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway

Cancer cachexia as a metabolic syndrome can lead to at least 25% of cancer deaths. The inhibition of muscle atrophy is a main strategy to treat cancer cachexia. In this process, myostatin (MSTN) can exert a du...

Source: Skeletal Muscle - March 28, 2019 Category: Research Authors: Dong Liu, Xinran Qiao, Zhijuan Ge, Yue Shang, Yi Li, Wendie Wang, Minghua Chen, Shuyi Si and Shu-zhen Chen Tags: Research Source Type: research